Evaluation of long-term clinical and health service outcomes following coronary artery revascularisation in Western Australia (WACARP): a population-based cohort study protocol by Gardner, C et al.
 
Evaluation of long-term clinical and health service outcomes
following coronary artery revascularisation in Western Australia
(WACARP): a population-based cohort study protocol
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Gardner, C, J M Rankin, E Geelhoed, M Nguyen, M Newman, D
Cutlip, M W Knuiman, T G Briffa, M S T Hobbs, and F M
Sanfilippo. 2014. “Evaluation of long-term clinical and health
service outcomes following coronary artery revascularisation in
Western Australia (WACARP): a population-based cohort study
protocol.” BMJ Open 4 (10): e006337. doi:10.1136/bmjopen-
2014-006337. http://dx.doi.org/10.1136/bmjopen-2014-006337.
Published Version doi:10.1136/bmjopen-2014-006337
Accessed February 17, 2015 3:27:37 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:13347524
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAAEvaluation of long-term clinical and
health service outcomes following
coronary artery revascularisation in
Western Australia (WACARP): a
population-based cohort study protocol
C Gardner,
1 J M Rankin,
2 E Geelhoed,
1 M Nguyen,
3 M Newman,
4 D Cutlip,
5
M W Knuiman,
1 T G Briffa,
1 M S T Hobbs,
1 F M Sanfilippo
1
To cite: Gardner C,
Rankin JM, Geelhoed E, et al.
Evaluation of long-term
clinical and health service
outcomes following coronary
artery revascularisation in
Western Australia (WACARP):
a population-based cohort
study protocol. BMJ Open
2014;4:e006337.
doi:10.1136/bmjopen-2014-
006337
▸ Prepublication history for
this paper is available online.
To view these files please
visit the journal online
(http://dx.doi.org/10.1136/
bmjopen-2014-006337).
Received 8 August 2014
Accepted 19 August 2014
For numbered affiliations see
end of article.
Correspondence to
Assoc Prof Frank Sanfilippo;
frank.sanfilippo@uwa.edu.au
ABSTRACT
Introduction: Coronary artery bypass grafting (CABG)
and percutaneous coronary interventions (PCI) are
procedures commonly performed on patients with
significant obstructive coronary artery disease to relieve
symptoms of ischaemia, improve survival or both.
Although the efficacy of both procedures at the individual
level has been established, the impact of advances in
coronary artery revascularisation procedures (CARP) on
long-term outcomes and cost-effectiveness at the
population level are yet to be assessed. Our aim is to
evaluate a minimum of 6-year outcomes and costs for
the total population of patients who had CARP in Western
A u s t r a l i a( W A )i n2 0 0 0 –2005.
Methods and analysis: This retrospective population
cohort study will link clinical and administrative health
data for a previously defined cohort including all patients
in WAwho had a CARP in the period 2000–2005. The
cohort consists of 19 014 patients who had 21 175
procedures (15 429 PCI and 5746 CABG). We are now
collecting a minimum of 6 years follow-up of morbidity
and mortality data for the cohort using the WA Data
Linkage System, clinical registries and hospital records,
with 12 years follow-up for cases in the year 2000.
Comparison of long-term outcomes for different CARP
will be reported (PCI vs CABG; bare metal stents vs drug-
eluting stents vs CABG). Cost-effectiveness analysis of
CARP from the perspective of the healthcare sector will
be performed using individual level cost data and average
costs from Australian Refined Diagnosis Related Groups.
Ethics and dissemination: This study has received
ethics approval from the University of Western Australia,
the Western Australian Department of Health and all
participating hospitals. Being a large population cohort
study, approval included a waiver of informed consent.
All findings will be presented at local, national and
international healthcare/academic conferences and
published in peer-reviewed journals.
INTRODUCTION
Coronary artery bypass grafting (CABG) and
percutaneous coronary intervention (PCI) are
established methods of mechanical
revascularisation for coronary artery disease,
yet their comparative effectiveness in terms of
long-term clinical outcomes and cost-
effectiveness remains unclear.
1–3 P C Ii sal e s s
invasive method than CABG and initially
involved the use of balloon angioplasty in the
1980s followed in the 1990s by the introduction
of coronary artery stents. Bare metal stents
( B M S )w e r eu s e di n i t i a l l y ,a n di nW e s t e r n
Australia (WA), these were largely replaced by
drug-eluting stents (DES) from mid-2002. DES
devices have a slow-release drug with antimito-
tic drug properties embedded in the stent
matrix to reduce the risk of stent restenosis
compared with BMS. Collectively, CABG and
PCI are referred to as coronary artery revascu-
larisation procedures (CARP).
A major disadvantage of PCI compared
with CABG is its higher rates of repeat
Strengths and limitations of this study
▪ A comparison of trends for a minimum of 6-year
clinical outcomes following bypass surgery, bare
metal stents and drug-eluting stents will be the
first such study in the total coronary artery
revascularisation population.
▪ Linkage of routinely collected state-wide health
administrative data with clinical registries allows
the ascertainment of accurate and complete data
on long-term outcomes for the cohort.
▪ This study avoids many limitations of clinical
trials including restricted patient samples, short
follow-up periods and relatively small numbers,
and will provide valuable information about
patients typically excluded from clinical trials.
▪ Given that this is an observational cohort study,
there is potential for bias due to the non-
randomised assignment to a treatment, but this
will be addressed through propensity score
methods.
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Open Access Protocolrevascularisation due to restenosis in treated vessels, and
this has contributed to the rise in CARP rates. Repeat pro-
cedures within 12 months were required in about 30% of
balloon angioplasty cases, compared with 15% for BMS
and 5% for DES procedures.
45Pivotal clinical trials have
shown superiority at 12 months for DES over BMS in
reducing in-stent restenosis and hence target vessel revas-
cularisation (TVR: treatment of the same vessel that was
treated previously).
67Concerns about the long-term
safety of DES were raised with several reports at the
European Society of Cardiology meeting in 2006 suggest-
ing increased late mortality possibly due to late stent
thrombosis.
67A later report from a large registry study in
Sweden (SCAAR study group) noted similar ﬁndings.
8
Subsequent studies applying uniform deﬁnitions for late
stent thrombosis from the Academic Research
Consortium
9 suggested a slight increase in risk for stent
thrombosis beyond 1 year (very late stent thrombosis) for
DES, but no increase in overall stent thrombosis or mor-
tality rates.
81 0 –12 Parallel results from multiple large regis-
tries, including a more complete follow-up from the
Swedish registry, have also indicated no increase in mor-
tality for DES compared with BMS.
13–15 However, the
issue of very late stent thrombosis remains a concern.
16
Despite the worldwide use of DES in millions of patients
to reduce the risk of TVR, little is known of the rates and
risk factors for late stent thrombosis and how these vary
over time. Complicating the real-world impact of very late
stent thrombosis associated with DES is the widespread
use of DES in off-label situations, variation and duration
of antiplatelet therapy and inadequate follow-up periods
in clinical trials to quantitate the risk of early stent throm-
bosis (≤30 days), late stent thrombosis (31–365 days) and
very late stent thrombosis (>1 year). It also appears that
the mechanisms leading to very late stent thrombosis are
distinct from those responsible for early or late stent
thrombosis.
17 First generation DES releasing sirolimus or
paclitaxel have a steady annual risk of stent thrombosis of
0.3–0.6% per year for at least 5 years.
16 18 19
CARP constitute a signiﬁcant component of the health
costs of coronary heart disease (CHD), which consumes
approximately 3% of total healthcare expenditure in
Australia.
20 While the efﬁcacy of CARP has been demon-
strated through clinical trials and meta-analyses, the impact
of advances in CARP on the adverse long-term outcomes
of cardiovascular disease (CVD), health service utilisation,
health costs and cost-effectiveness has not been assessed in
t h ep o p u l a t i o n .N o rh a v ea d v a n c e si nr e v a s c u l a r i s a t i o n
technology, particularly DES, been evaluated in terms of
clinical outcomes and cost-effectiveness within the total
population undergoing coronary revascularisation.
Assessment of the comparative effectiveness and out-
comes in populations undergoing CARP from case
series, registries and randomised controlled trials
(RCTs) is difﬁcult and the generalisability of results to
the general population can be problematic. Most studies
examine either PCI or CABG, although in some cases
direct comparisons between different revascularisation
procedures are carried out.
12 12 2Results from RCTs fre-
quently suffer from poor generalisability because of the
highly selective nature of patients who participate in
trials. Many RCTs exclude patients with cardiogenic
shock, left main coronary artery disease, concomitant
valvular disease and severe complex lesions, unsuitable
for stenting, but who would have beneﬁted from
surgery.
23 24 To a large extent, these studies exclude
patients with more severe CHD who have shown a sur-
vival beneﬁt from surgery, effectively biasing these trials
against the prognostic beneﬁt of CABG.
25 Furthermore,
despite evidence of the continued risk of stent throm-
bosis and other long-term adverse events, many clinical
trials have short follow-up periods of insufﬁcient length
to capture important clinical events. In addition, pivotal
RCTs that have informed clinical decision-making have
relatively small sample sizes and were underpowered to
detect rare events such as stent thrombosis.
The WA Data Linkage System
26 provides a unique
opportunity to examine the long-term outcomes of CARP
in a large population by linking routinely collected state-
wide health administrative data with clinical registries for
all CARP performed in WA. We will assess the long-term
comparative effectiveness of CARPs in the total popula-
tion of patients undergoing revascularisation procedures.
We will also examine the costs and cost-effectiveness of
CARP in the context of a wide range of covariates.
OBJECTIVES
An established population cohort of WA residents who
had a CARP in the period 2000–2005 will be used to
examine the long-term outcomes and costs using data
from the WA Data Linkage System, clinical registries,
patient level costs and hospital notes. The objectives of
the study are:
1. To evaluate the long-term (6 years for the entire cohort
and up to 12 years follow-up for varying fractions of the
cohort) clinical outcomes following the ﬁrst CARP in
WA adjusting for diagnosis, type of procedure and
demographic characteristics including age, gender,
socioeconomic status, location and Aboriginal status.
2. To describe the epidemiological and clinical determi-
nants of long-term trends in health service utilisation
and costs following ﬁrst admissions for CHD, includ-
ing the impact of changing revascularisation technol-
ogy and medical treatment.
3. To determine the long-term cost-effectiveness of dif-
ferent CARP (BMS vs DES vs CABG, and PCI vs
CABG).
METHODS
Study cohorts
In WA (population 1.95 million in 2003), CARP are per-
formed exclusively in three adult teaching hospitals and
four private hospitals, all located in the Perth metropol-
itan area. We have previously collected a detailed data
set on all patients who had a CARP at any of these seven
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impact of the introduction of DES on short-term out-
comes following CARP.
27 The current study runs from
2011 to 2015 and will use this cohort (WACARP cohort)
to obtain data on outcomes and costs from long-term
follow-up to be applied in analyses of clinical outcomes
and cost-effectiveness. The WACARP cohort consists of
19 014 patients who had 21 175 procedures (5746 CABG
and 15 429 PCI) during 2000–2005 (see table 1).
The Hospital Morbidity Data Collection (HMDC) is one
of the core data sets of the WA Data Linkage System
26 and
consists of all admissions to every hospital in WA (public
and private) since 1980. Diagnoses and procedures are
coded on discharge using the International Classiﬁcation
of Diseases (ICD) manuals, and represent discharge diag-
noses rather than presenting conditions. Coding at dis-
charge is a distinct advantage in that the use of admission
diagnosis to deﬁne an admission as CHD-associated is
problematic since patients often have diagnoses that
change during admission as a result of additional clinical
consideration and investigation. We have obtained from
the HMDC an extract of all cardiovascular admissions
since 1980. The PCI and CABG admissions in the
WACARP cohort were identiﬁed from this extract using
procedure codes from the ICD 10th revision Australian
Modiﬁcation (ICD-10-AM). Codes were: (1) 35304-00,
35305-00 (balloon angioplasty); (2) blocks 669 and 671
(angioplasty with stents) and (3) blocks 672–679 (CABG).
The WACARP cohort has been linked to all corre-
sponding records in the HMDC cardiovascular extract
and the linkage will be used to identify the ﬁrst (index)
admission for PCI or CABG in the cohort during 2000–
2005 by applying a ﬁxed lookback period of 10 years.
Any person in the WACARP cohort who has an admis-
sion for PCI or CABG in the previous 10 years will be
excluded to produce the Index WACARP Cohort. Index
cases will be classiﬁed as either PCI (BMS or DES) or
CABG. If a patient had both a PCI and CABG in their
index admission, we will classify them according to
which procedure came ﬁrst. All patients in the cohort
will be followed identically regardless of CARP status.
Patients who were non-WA residents (identiﬁed by
residential postcode from the HMDC) will be excluded
from the index cohort.
In addition, the HMDC extract of cardiovascular
admissions will allow us to identify the total cohort of
people aged from 25 years ever admitted to hospital
with a discharge diagnosis of CHD (ICD-9-CM codes
410-414, ICD-10-AM codes I20-I25) in any diagnosis ﬁeld
in the period 1980-2010 (Total CHD cohort).
Data sources and ongoing collection of outcome and
covariate variables
This study is adding to data collected previously for the
WACARP cohort in order to assess long-term outcomes
following a CARP. Data will come from both clinical
sources (eg, registries) and from the WA Data Linkage
System (HMDC extract of cardiovascular admissions and
death record). Clinical data for PCI procedures are being
obtained from the seven CARP hospitals. These include
electronic data from registries maintained by cardiology
departments at the three teaching hospitals (collection
completed), as well as the ongoing data collection from
medical notes of the private hospitals. Electronic clinical
data for the CABG cases have been obtained from regis-
tries maintained by departments of cardiothoracic
surgery and anaesthesia (perfusion) at the teaching hos-
pitals. Information about CABG performed privately
(40%) was unable to be obtained. Missing or inconsistent
data from electronic sources were queried with data cus-
todians from the corresponding hospital, and amended
where possible. All of these data sets (electronic and
notes) will be linked to their corresponding HMDC and
death records using the patient’s unique medical record
number and procedure date as the linkage ﬁelds.
Clinical details of PCI procedures from private hospitals
are collected from billing sheets, medical notes (hospital
and/or cardiologist notes), the radiographer’s journal,
nursing intervention records, as well as the cardiologist’s
procedure notes. The aggregated minimum data set of
PCI and CABG cases includes: residential postcode, age,
gender, admission and discharge dates, type of hospital,
type of admission, discharge diagnosis and procedure
codes (for current diagnosis and medical history including
Table 1 Number (and percentage of total CARP) of revascularisation procedures in the total WACARP cohort of 2000–2005
Type of procedure
Year of procedure
Total 2000 2001 2002 2003 2004 2005
BMS only 1798 (56.1) 1942 (60.9) 1563 (46.1) 412 (11.4) 116 (3.0) 114 (2.9) 5945
DES (±BMS) 0 0 627 (18.5) 2145 (59.5) 2795 (72.3) 2865 (73.2) 8432
Total stents 1798 (56.1) 1942 (60.9) 2190 (64.6) 2557 (70.9) 2911 (75.3) 2979 (76.1) 14 377
POBA/rota 244 (7.6) 169 (5.3) 126 (3.7) 60 (1.7) 34 (0.9) 54 (1.4) 687
Missing PCI type 54 (1.7) 45 (1.4) 63 (1.9) 55 (1.5) 58 (1.5) 90 (2.3) 365
Total PCI 2096 (65.4) 2156 (67.6) 2379 (70.1) 2672 (74.1) 3003 (77.7) 3123 (79.8) 15 429
CABG 1109 (34.6) 1034 (32.4) 1013 (29.9) 934 (25.9) 864 (22.3) 792 (20.2) 5746
Total CARP 3205 3190 3392 3606 3867 3915 21 175
BMS, bare metal stent; CABG, coronary artery bypass grafting; CARP, coronary artery revascularisation procedures; DES, drug-eluting stent;
PCI, percutaneous coronary intervention (stents+POBA/rota); POBA, plain old balloon angioplasty; rota, rotablator (rotational atherectomy).
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number of vessels grafted, type of grafts used (venous,
arterial), number and details of stents inserted (name,
brand, diameter, length), and date and cause of death.
These data will be enhanced by linking the following
from electronic sources:
1. Results of diagnostic tests from public and private path-
ology laboratories including type (inpatient/out-
patient), troponin I, troponin T, creatine kinase,
creatine kinase MB, serum creatinine, fasting glucose,
haemoglobin, total cholesterol, high-density lipopro-
tein, low-density lipoprotein (calculated), triglycerides,
estimated glomerular ﬁltration rate, total white cell
count, glycosylated haemoglobin;
2. Blood products (packed red blood cells, whole
blood, fresh frozen plasma, platelets and cryoprecipi-
tate including quantity and date issued) used to treat
bleeding complications following CARP (obtained
from the transfusion medicine databases at
hospitals);
3. Discharge and outpatient medications recorded in
electronic hospital pharmacy databases (drug, dose,
directions, date dispensed, quantity);
4. Presence of stent thrombosis from long-term
follow-up.
Follow-up and outcomes
Outcomes will be ascertained from a combination of
HMDC and death records, hospital notes and electronic
sources stated above. Follow-up events over 6 years for index
CARP cases will include: (1) death (CVD and all-cause); (2)
hospital admission for myocardial infarction (MI); (3) hos-
pital admission for TVR; (4) hospital admission for stroke;
(5) composites: death or MI, death or TVR, death or MI or
TVR, death or MI or TVR or stroke and (6) stent throm-
bosis according to the Academic Research Consortium def-
inition.
9 For index PCI cases, a TVR end point is deﬁned as
a subsequent PCI procedure in the same vessel as in the
index PCI (as identiﬁed from clinical data from notes or
electronic sources), or as any subsequent CABG procedure
(identiﬁed from HMDC), whichever was ﬁrst. For index
CABG cases, a TVR end point is any subsequent PCI or
CABG procedure (identiﬁed from HMDC). Two analyses
will be undertaken. For the ﬁrst, follow-up will cease on the
date of an outcome/end point within 6 years of the index
date or at the end of the 6-year period. Patients will be cen-
sored if the outcome does not occur during follow-up. A
separate analysis will be performed using as much follow-up
time as is available to 12 years.
Stent thrombosis
Our large number of PCI cases (n=15 429) will allow
evaluation of the frequency and predictors of early
(≤30 days), late (31 days to 1 year) and very late
(>1 year)
9 stent thrombosis and its impact on mortality
and MI outcomes for BMS compared with DES.
Follow-up for very late stent thrombosis will be for at
least 6 years and up to 12 years. Cases to review will be
identiﬁed from the linked HMDC and death data sets.
Data to determine the presence of stent thrombosis will
be collected by cardiology fellows/trainees from angio-
gram ﬁlms stored electronically or in medical notes at
each of the seven hospitals mentioned previously and
entered into an online database. Stent thrombosis will
be classiﬁed as deﬁnite, probable, possible and not
present according to the Academic Research
Consortium deﬁnition.
9
Comorbidities
The HMDC will be used to identify previous admissions
within 5 years of the index CARP where the discharge
diagnosis was recorded as MI, stroke, diabetes, renal
failure, congestive heart failure, peripheral vascular
disease or chronic obstructive pulmonary disease in any
diagnosis ﬁeld. Similarly, a Charlson comorbidity score
28
will be calculated as a composite measure of comorbidity
for each index case by applying a ﬁxed 5-year lookback
period using the HMDC. We will use the
Dartmouth-Manitoba ICD code assignments
29 in calcu-
lating the Charlson score based on the original 17
Charlson comorbidities.
Socioeconomic status and residential location
The HMDC includes variables for measuring socio-
economic status and residential remoteness by supplying
values for Socio-Economic Indexes for Areas (SEIFA)
30
and the Accessibility/Remoteness Index of Australia
(ARIA+)
31 based on census years beginning from 1996.
These are derived from the residential address and the
SEIFA will be used to measure quintiles of socio-
economic disadvantage, while ARIA+ will be used as a
measure of geographical disadvantage grouped into ﬁve
categories (major cities, inner regional, outer regional,
remote and very remote).
Estimation of resource use and costs
Only direct health system costs will be considered, to
reﬂect the perspective of the health sector,
32 including
hospital admissions and selected medical treatments
shown to be protective against adverse CVD events in
clinical trials. Resource costs have been obtained from
teaching hospitals for individual patient admissions and
include ward costs; pharmaceuticals; procedural costs;
and intensive care, theatre and staff salaries. In addition,
the HMDC includes the Australian Reﬁned Diagnosis
Related Group (AR-DRG) code for each admission.
From this, we can obtain the corresponding AR-DRG
cost,
33 which is the average cost of admissions with the
same AR-DRG.
General data analysis
Outcomes will be compared between: (1) PCI versus
CABG; (2) BMS versus DES, BMS versus CABG, DES
versus CABG; (3) pre-DES period (1 January 2000 to 30
June 2002) versus DES period (1 July 2002 to 31
December 2005; table 2) and (4) calendar year of index
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BMS, CABG, total PCI, total CARP). Comparisons will
be repeated by stratifying by: (1) Aboriginal status; (2)
single vessel disease versus multivessel disease; (3) quin-
tiles of socioeconomic disadvantage from SEIFA scores
and (4) residential location from ARIA+ categories.
Kaplan–Meier survival curves will be used to compare
time to outcome events in the Index WACARP Cohort.
Log-rank statistics will be used to test for crude differ-
ences. Cox proportional hazards regression models will
be used to compare groups after adjustment for covari-
ates including: (1) age; (2) sex; (3) Charlson score, and
previous comorbidity (as separate binary variables) for
any form of CVD, diabetes, chronic renal failure and
chronic obstructive pulmonary disease noted in the
5 years prior to the index admission; (4) diagnosis at
index admission (MI, not MI); (5) type of index admis-
sion (booked, emergency); (6) type of hospital at index
admission (public, private); (7) year of index admission;
(8) quintiles of socioeconomic disadvantage at index
admission; (9) ARIA+ category; (10) Aboriginal status;
(11) indication for CARP; (12) results of cardiac biomar-
kers and other laboratory tests at index admission; (13)
details of index CARP (including type of stent used,
total number of stents, length of stent); (14) severity of
illness (site of revascularisation, number of vessels
treated) and (15) use of cardioprotective drugs.
Adjusted Cox survival curves for comparison groups will
be plotted from outputs of the Cox regression models
using the mean for continuous covariates and the value
of the reference level for categorical covariates.
In addition to standard confounder adjustment in Cox
regression models, we will also adjust for covariates using
propensity score methods
34 to assess the sensitivity of the
group comparisons (ie, the estimated HRs) to the form
of adjustment for covariates. Standard confounder
adjustment may not work well when there is little
overlap in distribution of covariates across comparison
groups. Adjustment for propensity score performs better
in these circumstances. Any variable that may be asso-
ciated with the propensity of a treatment being selected
will be identiﬁed via logistic regression methods and the
propensity score for each patient obtained from the
ﬁtted logistic model. Once the propensity scores have
been calculated, outcomes will be analysed by Cox pro-
portional hazards regression with the propensity score
and treatment group as independent variables in the
model.
Economic analyses
The effect of total CARP and procedure type (CABG,
balloon angioplasty, BMS, DES, coronary angiography,
no procedure) within 90 days of the date of ﬁrst admis-
sion will be examined on subsequent 6-year costs in the
index WACARP cohort. Health costs and health service
utilisation will be classiﬁed as initial (occurring in the
ﬁrst 90 days) and long-term (>90 days to 6 years). The
90-day initial episode will allow for readmissions for
booked procedures from the initial clinical event.
Previous research has shown that approximately 95% of
CARP performed within 1 year of MI occur within
90 days.
35 Costs will be further characterised as: (1)
cardiac (or complications related to treatment); (2)
other CVD and related conditions (diabetes, renal
disease, chronic obstructive pulmonary disease) and (3)
not CVD or related conditions.
Age-speciﬁc trends in ﬁrst admissions for CHD will be
analysed to determine the extent to which overall health
utilisation and health cost are attributed to changes in
incidence and survival over time. Trends in the preva-
lence of CARP by age, sex, diagnosis and procedure at
90 days in the population which had a CHD-related
admission during 2000–2005 will also be determined to
investigate changes in patient selection.
Cost analysis will be undertaken to explore the cost
proﬁles of different service provision, and to assess the
impact of parameters such as diagnosis, age, sex, socio-
economic status, Aboriginality, hospital type (public or
private), admission type, cardioprotective drug therapy
and comorbidity on the total cost of care. This will
guide stratiﬁcation of the cohort into meaningful sub-
groups for more detailed analyses. Costs will be adjusted
to 2013 dollars by inﬂating the costs from previous years
using the corresponding Health Price Index obtained
from the Australian Institute of Health and Welfare.
Costs and outcomes compared across differing time
periods will be adjusted for time preference using a 3%
discount rate. Sensitivity analyses will investigate varying
discount rates of 0% and 5%.
In general, costs are difﬁcult to analyse alongside
other parameters such as disease severity and age
because of: (1) the distribution of data (data are usually
skewed, with a few patients accounting for a dispropor-
tionate share of the total cost); (2) problems in dealing
with censored data (patients who die do not continue to
incur costs) and (3) the nature of cost accrual, which is
irregular and may depend on different factors at
Table 2 Uptake of DES in Western Australia from 2002 onwards (count and percentage of total stents)
Type of stent
Year of procedure
Total 2000 2001 2002 2003 2004 2005
BMS only 1798 (100) 1942 (100) 1563 (71.4) 412 (16.1) 116 (4.0) 114 (3.8) 5945 (41.4)
DES (±BMS) 0 0 627 (28.6) 2145 (83.9) 2795 (96.0) 2865 (96.1) 8432 (58.6)
Total stents 1798 1942 2190 2557 2911 2979 14 377
BMS, bare metal stent; DES, drug-eluting stent.
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of costs will use mean and median values compared by
stratifying on important variables including age, sex,
disease severity and Charlson score. More sophisticated
models including generalised linear models (GLMs)
and Cox proportional hazards regression will be used to
adjust for covariates and produce results that are directly
interpretable (ie, not log results that have to be
back-transformed).
Cox models have been used for economic analyses
since cost distributions are frequently complex and difﬁ-
cult to describe parametrically.
36 Cox proportional
hazards models make no parametric assumptions about
the speciﬁc error distribution. Furthermore, if a patient
dies prior to hospital discharge and complete costs are
not obtained, the patient will be censored in the model.
Although Cox proportional hazards models can deal
with both censored and complex cost distributions,
irregular cost accrual may lead to bias in survival esti-
mates. Even though the bias may be small, its magnitude
cannot be estimated.
36 GLMs have recently been intro-
duced in cost data analysis and will be the main models,
with appropriately speciﬁed GLMs modelling the error
structure of cost data more closely.
37 GLMs are particu-
larly attractive for regression of cost data because they
provide parametric methods of analysis where a variety
of non-normal distributions can be speciﬁed and the
way covariates act can be altered. GLMs are also advanta-
geous because they make inferences about mean costs
directly as is appropriate for health economic
decision-making.
Incremental cost-effectiveness ratios (ICERs) will be
compared between groups and across measures of sever-
ity of disease, and adjusted for age, comorbidity and
other covariates at the index admission. Since cumula-
tive costs and effects for CARPs are dependent on the
time interval under consideration, costs and effects will
be ascertained for a range of time periods: 0–90 days
(initial costs), 91 days to 1 year in 90-day survivors,
1–6 years in 1-year survivors and for total 6-year costs.
Follow-up of 6 years will capture the most relevant long-
term costs and effects of the two procedures. Modelling
will be used to extrapolate results to arrive at lifetime
cost-effectiveness estimates.
Sensitivity analysis and acceptability
The robustness of results of the cost-effectiveness ana-
lyses to parameter uncertainty will be examined using
probabilistic sensitivity analysis incorporating bootstrap-
ping, since it is more powerful than deterministic sensi-
tivity analysis.
38 Bootstrap methods will be used to
estimate the joint distribution of cost and effectiveness
differences, and the proportion of replicates with ICERs
less than commonly accepted benchmarks applicable to
Australia will be presented. Scatterplots showing the
joint distribution of incremental costs and incremental
effects between comparison groups for each of the main
outcomes will be calculated. In line with
recommendations by the National Institute for Clinical
Excellence, ICERs will also be summarised using accept-
ability curves.
39 These represent the probability (ie, pro-
portion of simulations) that a given intervention is more
cost-effective than alternative(s) for a range of
maximum thresholds of willingness to pay for an add-
itional outcome measure.
Dissemination
All ﬁndings will be presented at local, national and inter-
national healthcare/academic conferences and pub-
lished in peer-reviewed journals. Relevant ﬁndings will
also be disseminated through the clinical networks of
the cardiologists on the research team.
DISCUSSION
This study addresses two signiﬁcant issues about the
impact of increasing and changing coronary artery revas-
cularisation technology. First, the population analysis of
clinical outcomes and cost-effectiveness comparing spe-
ciﬁc CARP technologies will be of particular interest to
clinicians. The second, which examines the costs and
possible savings attributable to CARP in the context of a
wide range of environmental and medical factors that
affect the cost of CARP, will interest medical decision-
makers. Studies such as ours are limited to the few juris-
dictions in which population medical record linkage is
possible. As revascularisation technologies in Australia
during the study period were the same as those available
in other countries, the results of our population analysis
will be applicable in other jurisdictions throughout the
world.
While randomised clinical trials indicate that DES have
short-term clinical and health service advantages over
BMS, DES are more expensive and their use may there-
fore be restricted in practice. Moreover, there are still
unresolved questions about the possible longer term
complications of DES and whether the initial (1-year)
beneﬁts of DES are sustained over the longer term. The
future of CABG procedures, which have been declining
in absolute and relative terms compared with PCI over
many years, is also unclear. Finally, there has been no
population assessment of the impact of rapid increases in
concomitant medical treatment on outcomes of CARP.
This study will compare trends in clinical outcomes
following CABG, BMS or DES in a total CARP popula-
tion over 6 years and up to 12 years. It will use an exist-
ing large cohort of >19 000 patients treated with CARP
to show if improved outcomes in one or more of the
CARP types will translate into beneﬁts for the total
population of recipients and the healthcare sector. The
inclusiveness of our cohort (all CARP) and complete
ascertainment of data on outcomes and end points
during follow-up is a major strength of this study. The
ability to link procedural and clinical data with routinely
collected administrative data through the WA Data
6 Gardner C, et al. BMJ Open 2014;4:e006337. doi:10.1136/bmjopen-2014-006337
Open AccessLinkage System allows identiﬁcation of comorbid condi-
tions and outcome data that are continuously updated.
International studies of the role of technology on
rapidly increasing healthcare costs have paid particular
attention to the cost implications of new CARP technolo-
gies in CHD. However, while the short-term costs of
CARP in CHD can be readily determined, there have
been no previous studies of the long-term population
impact of such advances in treatment on subsequent
health service cost and utilisation. This study will help
deﬁne the optimal revascularisation strategy for patients
in the general population. Important preplanned sub-
group analysis will also provide valuable guidance on the
comparative effectiveness of PCI and CABG.
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